Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$32.39 +1.7%	$28.58	$23.42 ▼ $62.58	$1.88B	0.77	678,257 shs	760,666 shs
DAWN Day One Biopharmaceuticals	$6.39 -1.4%	$7.04	$6.08 ▼ $16.76	$647.70M	-1.24	1.11 million shs	1.21 million shs
KROS Keros Therapeutics	$14.27 +1.8%	$13.00	$9.12 ▼ $72.37	$579.58M	1.32	844,377 shs	480,221 shs
LGND Ligand Pharmaceuticals	$103.17 +2.2%	$104.67	$77.43 ▼ $129.90	$1.99B	0.87	116,070 shs	164,245 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+8.69%	+7.61%	-2.20%	-10.87%
DAWN Day One Biopharmaceuticals	0.00%	+1.91%	-19.42%	-22.55%	-51.85%
KROS Keros Therapeutics	0.00%	-2.06%	-2.59%	+28.56%	-69.55%
LGND Ligand Pharmaceuticals	0.00%	+1.55%	-5.69%	-8.03%	+21.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.0252 of 5 stars	3.3	1.0	4.2	2.8	0.8	1.9
DAWN Day One Biopharmaceuticals	2.6159 of 5 stars	4.6	0.0	0.0	2.9	2.5	0.0
KROS Keros Therapeutics	2.2848 of 5 stars	3.3	1.0	0.0	2.1	5.0	0.0
LGND Ligand Pharmaceuticals	4.7827 of 5 stars	3.5	3.0	4.4	3.7	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.56	Moderate Buy	$56.00	72.89% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	378.43% Upside
KROS Keros Therapeutics	2.57	Moderate Buy	$37.00	159.29% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.14	41.65% Upside

Current Analyst Ratings Breakdown

Latest AGIO, KROS, LGND, and DAWN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $25.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00
5/7/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $27.00
5/2/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$74.00 ➝ $71.00
4/10/2025	LGND Ligand Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$143.00
4/9/2025	KROS Keros Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$43.00 ➝ $25.00
4/3/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/1/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00 ➝ $15.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$37.04M	50.65	N/A	N/A	$27.02 per share	1.20
DAWN Day One Biopharmaceuticals	$161.92M	4.00	N/A	N/A	$3.98 per share	1.61
KROS Keros Therapeutics	$214.71M	2.70	N/A	N/A	$11.09 per share	1.29
LGND Ligand Pharmaceuticals	$181.49M	10.97	$4.23 per share	24.39	$40.39 per share	2.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	2.86	N/A	N/A	1,845.92%	-2.51%	-2.26%	8/7/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$188.92M	-$0.71	N/A	N/A	N/A	N/A	-22.40%	-19.79%	7/8/2025 (Estimated)
KROS Keros Therapeutics	-$152.99M	-$0.18	N/A	N/A	N/A	-27,890.94%	-41.74%	-38.42%	8/6/2025 (Estimated)
LGND Ligand Pharmaceuticals	$52.15M	-$7.12	41.10	27.81	N/A	29.68%	4.95%	4.39%	8/5/2025 (Estimated)

Latest AGIO, KROS, LGND, and DAWN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	11.90	11.56
DAWN Day One Biopharmaceuticals	N/A	14.62	14.55
KROS Keros Therapeutics	N/A	19.03	19.03
LGND Ligand Pharmaceuticals	N/A	12.49	11.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
DAWN Day One Biopharmaceuticals	87.95%
KROS Keros Therapeutics	71.56%
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
DAWN Day One Biopharmaceuticals	6.20%
KROS Keros Therapeutics	20.60%
LGND Ligand Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	54.47 million	Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	92.38 million	Optionable
KROS Keros Therapeutics	100	40.62 million	31.23 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.78 million	Optionable

AGIO, KROS, LGND, and DAWN Headlines

Recent News About These Companies

Summit Global Investments Acquires 6,407 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 1 at 6:17 AM | marketbeat.com

Kings Path Partners LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 31 at 6:11 AM | marketbeat.com

Squarepoint Ops LLC Purchases Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 31 at 3:55 AM | marketbeat.com

Bank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 25, 2025 | marketbeat.com

Castleark Management LLC Cuts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 23, 2025 | marketbeat.com

Graham Capital Management L.P. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 18, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by Brokerages

May 18, 2025 | marketbeat.com

Deutsche Bank AG Purchases 15,160 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 16, 2025 | marketbeat.com

Janus Henderson Group PLC Acquires 5,929 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 15, 2025 | marketbeat.com

Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.com

May 15, 2025 | marketbeat.com

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025 | globenewswire.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Acquires $156,090.00 in Stock

May 14, 2025 | insidertrades.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Northern Trust Corp

May 13, 2025 | marketbeat.com

LGND: 1Q:25 Results

May 12, 2025 | msn.com

Clark Capital Management Group Inc. Increases Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 12, 2025 | marketbeat.com

Driehaus Capital Management LLC Increases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 11, 2025 | marketbeat.com

Baird Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

May 11, 2025 | marketbeat.com

Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2025 Earnings Guidance

May 10, 2025 | marketbeat.com

Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

May 9, 2025 | finance.yahoo.com

Q1 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript

May 9, 2025 | gurufocus.com

Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings

May 8, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO, KROS, LGND, and DAWN Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$32.39 +0.55 (+1.73%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$32.09 -0.30 (-0.93%)

As of 03:59 AM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.39 -0.09 (-1.39%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$6.38 -0.01 (-0.16%)

As of 03:59 AM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Keros Therapeutics NASDAQ:KROS

$14.27 +0.25 (+1.78%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$14.15 -0.12 (-0.84%)

As of 04:00 AM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Ligand Pharmaceuticals NASDAQ:LGND

$103.17 +2.26 (+2.24%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$102.19 -0.98 (-0.95%)

As of 04:00 AM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time